Roche in $44 billion bid for remainder of Genentech
This article was originally published in Scrip
Executive Summary
Swiss pharma Rochehas offered to buy the 44% of its US partner Genentechthat it does not already own for $43.7 billion as it seeks to better leverage the pipeline and R&D of the biotech bellwether. Roche acquired a majority interest in Genentech in 1990.